《大行報告》花旗降華潤醫療(01515.HK)評級至「中性」 目標價下調至6.6元
花旗發表報告表示,華潤醫療(01515.HK)今年上半年業績表現遜預期,雖然收入按年增長5%至9.65億元人民幣,但純利按年下跌9%至1.83億元人民幣。而毛利率、經營利潤率以至純利率亦錄得下降。
該行下調對華潤醫療之評級,由「買入」降至「中性」,目標價由12.5元大幅下調至6.6元,此按現金流折現率作估值。此外,經調整各類型醫院的銷售趨勢後,該行又下調對華潤醫療今年至2021年的每股盈利預測分別17%、21%及24%。
花旗表示,在內地政府控制預算的情況下,對華潤醫療現有醫院的運營持謹慎態度,而且其新醫院的收購依然低於預期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.